News

In medical research, especially in medical trials like those carried out by NZCR, it's important that people fully understand what a clinical trial involves, as well as the risks and benefits. So, before someone joins a clinical trial, NZCR must give potential participants all the details about the study.

In this edition of Clinical Chronicles, you’ll find updates on our focus on quality throughout the organisation, celebrate positive outcomes from recent studies, and we share some big news for Christchurch!

In this edition of Clinical Chronicles, you’ll find updates on our focus on quality throughout the organisation, celebrate positive outcomes from recent studies, and we share changes implemented that you have asked for.

NZCR's commitment to rigorous research and patient safety is reflected in the positive results emerging from several key studies. Here's a look at recent successes that underscore NZCR's dedication to advancing global health. 

A drug involved in the FLAMINGO Auckland study has received Orphan Drug Designation from the FDA for the treatment of Cystic Fibrosis. This is a major step forward in the journey to develop new treatments for this challenging genetic condition.

Professor Gane’s presence at APASL 2025 served as a powerful reminder of NZCR’s status as a world-class clinical research organisation.

Selarsdi, a biosimilar drug recently tested at NZCR for psoriasis and active psoriatic arthritis, has been granted approval for sale in 83 countries, including NZ. Thanks to all our participants for helping make this drug a reality, enabling access to millions more people worldwide. 

NZCR was recently involved in promising Phase-1 research of a new drug, TLC-2716, to treat people with severe high triglycerides and NASH. These promising early results, enables OrsoBio to move on to Phase-2a stage of testing with patients who have high triglycerides and liver fat.

Clinical trials are an incredibly important part of the process to bring new drugs to market and a participant’s safety is the number one priority in any clinical study.  Read about the safety protocols and checks completed throughout the trial process.

Before any new drug or medicine can be bought to market, the Sponsor or Developer must prove the drug does what it is intended to do, all side effects are known and understood, and it is safe for humans to take. This article outlines the clinical research processes and checks NZCR must follow to ensure trials are conducted safely and ethically.

New Zealand Clinical Research (NZCR) undertakes clinical trials in NZ for many medical and pharmaceutical groups around the world. This must be done under strict regulatory controls to ensure the medical trial is conducted safely, ethically, and with scientific rigour. Learn about the meticulous review process NZCR must undergo before they can start trialing any new drug.